Effect of sustained virological response to interferon therapy for hepatitis C to the hepatectomy for primary hepatocellular carcinoma

Hepato-Gastroenterology

Volumn 62, Issue 137, 2015, Pages 157-163

  Tsujita, Eiji ^a,b   Maeda, Takashi ^a   Kayashima, Hiroto ^a   Harada, Noboru ^a   Tsutsui, Shin Ichi ^a   Matsuda, Hiroyuki ^a   Kinjo, Nao ^b   Ikeda, Yasuharu ^b   Morita, Masaru ^b   Ishida, Teruyoshi ^a  

^a ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

HCV; Hepatectomy; Hepatocellular carcinoma; IFN; SVR

Indexed keywords

INTERFERON; ANTIVIRUS AGENT; BIOLOGICAL MARKER; VIRUS RNA;

AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; CARCINOMA, HEPATOCELLULAR; CHI SQUARE DISTRIBUTION; COMPLICATION; DRUG EFFECTS; GENETICS; HEPACIVIRUS; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; TIME; TUMOR RECURRENCE; VIROLOGY; VIRUS LOAD;

AGED; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; HEPACIVIRUS; HEPATECTOMY; HEPATITIS C; HUMANS; INTERFERONS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84928553948     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge14749     Document Type: Article

References (27)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132:2557-76.
2. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993;328:1797-801.
3. Imai Y, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med. 1998;29:94-9.
4. Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 1999;29:1124-30.
5. Coverdale SA, Khan MH, Byth K, et al. Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study. Am J Gastroenterol. 2004;99:636-44.
6. Sanefuji K, Kayashima H, Iguchi T, et al. J Surg Oncol. Characterization of hepatocellular carcinoma developed after achieving sustained virological response to interferon therapy for hepatitis C. J Surg Oncol. 2009;99:32-7.
7. Shirabe K, Takeishi K, Taketomi A, et al. Improvement of long-term outcomes in hepatitis C virus antibody-positive patients with hepatocellular carcinoma after hepatectomy in the modern era. World J Surg. 2011;35:1072-84.
8. Sakae M, Kubo S, Takemura S, et al. Effect of interferon therapy on first and second recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Hepatol Res. 2012;42:564-73.
9. Sugimachi K, Kinjo N, Ikebe M, et al. Significance of hepatic resection for hepatocellular carcinoma with sustained virological response to interferon therapy for chronic hepatitis C. Hepatol Res. 2013;43:605-9.
10. Liver Cancer Study Group of Japan. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer. Tokyo, Japan: Kanehara & Co., Ltd., 2008.
11. Edmondson HA, Steiner PE: Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954;7:462-503.
12. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
13. Yamashita Y, Taketomi A, Itoh S, et al. Longterm favorable results of limited hepatic resections for patients with hepatocellular carcinoma: 20 years of experience. J Am Coll Surg. 2007 Jul;205(1):19-26.
14. Takenaka K, Kawahara N, Yamamoto K, et al. Results of 280 liver resections for hepatocellular carcinoma. Arch Surg. 1996;131:71-6.
15. Taura K, Ikai I, Hatano E, et al. Implication of frequent local ablation therapy for intrahepatic recurrence in prolonged survival of patients with hepatocellular carcinoma undergoing hepatic resection: an analysis of 610 patients over 16 years old. Ann Surg. 2006;244:265-73.
16. Poon RT, Fan ST, Lo CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg. 2001;234:63-70.
17. Sasaki A, Iwashita Y, Shibata K, et al. Improved long-term survival after liver resection for hepatocellular carcinoma in the modern era: retrospective study from HCV-endemic areas. World J Surg. 2006;30:1567-78.
18. Adachi E, Maeda T, Matsumata T, et al. Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology. 1995;108:768-75.
19. Shirabe K, Takenaka K, Taketomi A, et al. Postoperative hepatitis status as a significant risk factor for recurrence in cirrhotic patients with small hepatocellular carcinoma. Cancer 1996;77:1050-1055.
20. Shirabe K, Shimada M, Kajiyama K, et al. Clinicopathologic features of patients with hepatocellular carcinoma surviving 10 years after hepatic resection. Cancer. 1998;83:2312-2316.
21. Shirabe K, Wakiyama S, Gion T, et al. Clinicopathological risk factors linked to recurrence pattern after curative hepatic resection for hepatocellular carcinoma - results of 152 resected cases. Hepatogastroenterology 2007;54:2084-2087.
22. Nishiguchi S, Tamori A, Kubo S. Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma. Intervirology. 2005;48:71-75.
23. Kubo S, Nishiguchi S, Hirohashi K, et al. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 2002;89:418-422.
24. Uenishi T, Nishiguchi S, Tamori A, et al. Influence of interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma. Hepatol Res. 2006;36:195-200.
25. Nishiguchi S, Shiomi S, Nakatani S, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet. 2001;357:196-7.
26. Yano H, Ogasawara S, Momosaki S, et al. Growth inhibitory effects of pegylated interferon alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int 2006;26: 964-975.
27. Shimada M, Hasegawa H, Gion T, et al. Risk factors of the recurrence of hepatocellular carcinoma originating from residual cancer cells after hepatectomy. Hepatogastroenterology. 1999; 46:2469-75.